2023
DOI: 10.1055/s-0043-1766136
|View full text |Cite
|
Sign up to set email alerts
|

Sorafenib-Induced Spiny Follicular Hyperkeratosis: A Case Report with Review of Literature

Abstract: Sorafenib is a multikinase inhibitor used in the treatment of various solid tumors. Mucocutaneous adverse events are experienced by 70 to 90% of the patients receiving sorafenib, underscoring the importance of awareness among oncologists and dermatologists. Spiny follicular hyperkeratosis (SFH) is a benign and rarely reported skin reaction linked to sorafenib. It is characterized by flesh-colored or white, follicular hyperkeratotic spicules, preferentially involving the face, scalp, upper trunk, and upper arms… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 30 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?